CN101837129A - Medicament composition containing cMet inhibitor, HDAC (Histone Deacetylases) inhibitor and EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and application thereof - Google Patents
Medicament composition containing cMet inhibitor, HDAC (Histone Deacetylases) inhibitor and EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and application thereof Download PDFInfo
- Publication number
- CN101837129A CN101837129A CN200910129317A CN200910129317A CN101837129A CN 101837129 A CN101837129 A CN 101837129A CN 200910129317 A CN200910129317 A CN 200910129317A CN 200910129317 A CN200910129317 A CN 200910129317A CN 101837129 A CN101837129 A CN 101837129A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- growth factor
- tyrosine kinase
- cancer
- kinase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a medicament composition containing a histone deacetylases (HDAC) inhibitor, a hepatocyte growth factor receptor (cMet) inhibitor, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor and application thereof in preparing the medicaments for treating liver cancer, lung cancer, colon cancer, kidney cancer, gastric cancer, brain tumor, sarcoma, pancreatic cancer, ovarian cancer, breast cancer or prostatic cancer. The medicament composition has the obvious synergistic effect, improves the curative efficiency of the medicaments, decreases the drug dosage and reduces the occurrence frequency of the side-effect.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition and the application in the medicine of preparation treatment cancer thereof, be specifically related to contain the pharmaceutical composition and the application in the medicine of preparation treatment hepatocarcinoma, pulmonary carcinoma, colon cancer, renal carcinoma, gastric cancer, cerebroma, sarcoma, cancer of pancreas, ovarian cancer, breast carcinoma or carcinoma of prostate thereof of C-MET HGFr (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor.
Background technology
World Health Organization's investigation report shows that global cancer condition is serious day by day, and 20 years from now on new patients' number will be increased to 1,500 ten thousand by present every year 1000 ten thousand, because of the number that cancer is dead also will be by increasing to 1,000 ten thousand 6,000,000 of every year.Wherein primary hepatocarcinoma is one of human modal malignant tumor for occurring in the epithelial canceration of hepatocyte and stones in intrahepatic bile duct; Pulmonary carcinoma is common malignancy, comes from bronchiolar epitheliums at different levels, is divided into cell lung cancer and nonsmall-cell lung cancer; Along with growth in the living standard, the change of dietary structure, the sickness rate of colon cancer is ascendant trend year by year.
The antitumor drug that has gone on the market at present is more, and as alkylating agent medicine, antimetabolite, antitumor antibiotics, immunomodulator etc., but medicine is because toxicity is bigger mostly, and patient does not tolerate.The Study on Molecular Mechanism that develops along with the generation to tumor is more and more clearer, and the multiple malignant tumor of molecular targeted treatment has been subjected to paying close attention to widely and paying much attention to.Molecular targeted agents selectivity height, wide spectrum are effective, and its safety is better than the cytotoxicity chemotherapeutics, are the new directions of present oncotherapy field development.
Hepatocyte growth factor (Hepatocyte growth factor, HGF) by with have the ability that promotes cell division, motion and shaping after special receptor (C-MET HGFr cMet) on its target cell combines.CMet is a proto-oncogene cMet encoded protein, is the transmembrane receptor that a class has the autonomy phosphorylation activity.HGF and cMet in conjunction with after induce cMet receptor tyrosine phosphorylation on the after birth, and the biological effect by signal transduction pathway performance HGF in the various kinds of cell, the generation of tumor cell, migrate and transfer process in brought into play important effect.Therefore, the activity that suppresses cMet may play important intervention effect to generation, invasion and attack and the transfer of tumor cell.At the cMet inhibitor that grinds or entered clinical research PF-02341066, SGX523 or PHA665752 etc. are arranged.
Antibiotic FR 901228 has the tumor cell proliferation of inhibition, cell cycle arrest, inducing cell differentiation and promotes apoptotic effect.Wherein SAHA goes on the market, and MS-275, LBH589, Trichostatin (TSA), FK228 and west reach multiple Antibiotic FR 901228s such as aniline and enter clinical research in addition.
EGF-R ELISA (epidermal growth factor receptor EGFR) plays an important role in the developing of tumor, it and part in conjunction with after, inspire cascade reaction and cause cell proliferation, angiogenesis, transfer and apoptosis to suppress.Comprise in the multiple solid tumor of nonsmall-cell lung cancer that normal mistake of EGFR gene expressed, the poor prognosis of this expression of gene and some tumor is relevant.The endocellular metabolism zone of epidermal growth factor recipient tyrosine kinase inhibitor and ATP reversibility competition tyrosine kinase, the automatic phosphorylation of inhibitory enzyme and the transmission of downstream signal.The medicine that has gone on the market is just like gefitinib (Gefitinib, Iressa), erlotinib (Erlotinib, Taceva) be approved for the treatment of nonsmall-cell lung cancer in late period, synergism does not appear in the therapeutic scheme that associating gefitinib or erlotinib and carboplatin+paclitaxel/cisplatin+gemcitabine is used for the nonsmall-cell lung cancer in late period, no significant difference on overall life span.
Along with the progress of oncomolecularbiology, the molecular targeted treatment of tumor has become the focus of tumor research, has brought into play important effect in the treatment of kinds of tumors.Yet, the biological behaviour of most of tumor is arranged by single signal transduction pathway, but a plurality of signal transduction pathway concur, therefore drug combination carries out targeted therapy at many target spots and will not only be intended to reduce or delay chemical sproof appearance, reduce toxicity, especially rational three coupling medicines will be obtained better therapeutic to the synergism that cancerous cell kills and wounds by multiple medicine.
Summary of the invention
At above technological deficiency; the invention provides a kind of pharmaceutical composition and treat hepatocarcinoma in preparation; pulmonary carcinoma; colon cancer; pulmonary carcinoma; renal carcinoma; gastric cancer; cerebroma; sarcoma; cancer of pancreas; ovarian cancer; application in the medicine of breast carcinoma or carcinoma of prostate is specially and contains C-MET HGFr (cMet) inhibitor; the pharmaceutical composition of histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor is in preparation treatment hepatocarcinoma; pulmonary carcinoma; colon cancer; renal carcinoma; gastric cancer; cerebroma; sarcoma; cancer of pancreas; ovarian cancer; application in the medicine of breast carcinoma or carcinoma of prostate.
The present invention contains in the pharmaceutical composition of C-MET HGFr (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) inhibitor, and described hepatocyte growth factor receptor inhibitor is PF-02341066, SGX523 or PHA665752 and respective analogs, derivant etc.; Described Antibiotic FR 901228 can be the medicine of the Antibiotic FR 901228 of any structure type, as hydroximic acid, cyclic peptide, benzamides, fatty acid etc., be specifically as follows but be not limited to as, suberoylanilide hydroxamic acid (SAHA), Trichostatin (TSA), LBH589, MS-275, depsipeptide (FK228), Aphacidin, depsipeptides, west reach aniline, sodium butyrate, phenylbutyrate sodium; Described epidermal growth factor recipient tyrosine kinase inhibitor is gefitinib, erlotinib, Canertinib or PKI166 and respective analogs, derivant etc.
Described C-MET HGFr (cMet) inhibitor in the pharmaceutical composition of the present invention can be the medicine of the cMet inhibitor of any structure type, as PF-02341066, SGX523 or PHA665752, wherein, SGX-523 has applied for that by the research and development of SGX Pharmaceuticals company the I phase is clinical; PHA-665752 is researched and developed by Sugen company.
C-MET HGFr in the pharmaceutical composition of the present invention (cMet) inhibitor is preferably: PF-02341066, its structural formula are I.
In the pharmaceutical composition of the present invention, described component is not limited to PF-02341066 medicine itself, can also be its pharmaceutically useful salt, the analog of the derivant of PF-02341066 or the various PF-02341066 disclosed in the WO2007066187 patent application.
Antibiotic FR 901228 is preferably SAHA, Trichostatin (TSA), LBH589 and MS-275 in the pharmaceutical composition of the present invention.
Wherein SAHA is JMC, 38,8,1995, and 1411-1413 and JMC, 48,15,2005, the chemical compound of the formula II of being put down in writing among the 5047-5051:
In the pharmaceutical composition of the present invention, described component is not limited to said medicine itself, can also be the salt of their hydrate, analog, derivant and other organic or inorganic.
Among the present invention, described EGF-R ELISA (EGFR) tyrosine kinase inhibitor can be the medicine of the epidermal growth factor recipient tyrosine kinase inhibitor of any structure type, as gefitinib, erlotinib, Canertinib or PKI166, wherein, Canertinib is the EGFR tyrosine kinase inhibitor, is researched and developed by Pfizer company; PKI-166, the EGFR tyrosine kinase inhibitor is researched and developed by Pfizer company.
Pharmaceutical composition mesocuticle growth factor recipient tyrosine kinase inhibitor of the present invention is preferably gefitinib or erlotinib or its combination, and wherein erlotinib is the chemical compound of the formula III put down in writing among the US 5747498;
In the pharmaceutical composition of the present invention, described component is not limited to said medicine itself, can also be the salt of their analog, derivant, free alkali and other organic or inorganic.
The present invention contains in the pharmaceutical composition of C-MET HGFr (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor, and the mol ratio of hepatocyte growth factor receptor inhibitor, Antibiotic FR 901228 and epidermal growth factor recipient tyrosine kinase inhibitor is 0.3-3.0: 0.5-4.0: 1.5-15; The present invention further mol ratio of preferred described hepatocyte growth factor receptor inhibitor, Antibiotic FR 901228 and epidermal growth factor recipient tyrosine kinase inhibitor is 0.75-1.5: 1.0-2.0: 3.0-7.5.
The pharmaceutical composition that the present invention contains hepatocyte growth factor receptor inhibitor, Antibiotic FR 901228 and epidermal growth factor recipient tyrosine kinase inhibitor can be used to prepare the medicine for the treatment of various tumors, and described tumor includes but not limited to hepatocarcinoma, pulmonary carcinoma, colon cancer, renal carcinoma, gastric cancer, cerebroma, sarcoma, cancer of pancreas, ovarian cancer, breast carcinoma or carcinoma of prostate.
The application that the pharmaceutical composition of the preferred C-MET HGFr of the present invention (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor is used for preparing the medicine for the treatment of hepatocarcinoma, pulmonary carcinoma and colon cancer.
In the application of the present invention in the medicine of preparation treatment hepatocarcinoma, pulmonary carcinoma, colon cancer, described hepatocyte growth factor receptor inhibitor PF-02341066, Antibiotic FR 901228 SAHA and epidermal growth factor recipient tyrosine kinase inhibitor erlotinib mol ratio are 0.75-1.5: 1.0-2.0: 3.0-7.5; The mol ratio that is preferably PF-02341066, SAHA and erlotinib is 1.0-1.5: 1.5-2.0: 5.0-7.5; More preferably PF-02341066, SAHA and erlotinib mol ratio are 1.5: 2.0: 7.5.
Contain C-MET HGFr (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor compositions are in preparation treatment hepatocarcinoma, pulmonary carcinoma, colon cancer, renal carcinoma, gastric cancer, cerebroma, sarcoma, cancer of pancreas, ovarian cancer, in the application of the medicine of breast carcinoma or carcinoma of prostate, in the scheme of the medicament of the present composition being made administration simultaneously, C-MET HGFr (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor can be contained in in a kind of pharmaceutical preparation such as tablet or the capsule, also can be with C-MET HGFr (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor are made preparation respectively, as making tablet or capsule respectively, and the mode that adopts this area routine is with their packings or combine, and the patient takes simultaneously according to the indication of package insert then; In the scheme of the medicament of the present composition being made administration successively, can be with C-MET HGFr (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor is made different preparations respectively with EGF-R ELISA (EGFR) tyrosine kinase inhibitor, and the mode that adopts this area routine is with their packings or combine, the patient takes according to the sequencing of package insert indication then, or three kinds of compositions in the above-mentioned composition are made a kind of preparation of controlled release, a kind of composition in elder generation's release composition, another kind of composition in the release composition again, and then discharging the third composition, the patient only need take this controlled release composition preparation; In the scheme of the medicament that the present composition is prepared into the intersection administration; can be with C-MET HGFr (cMet) inhibitor; histon deacetylase (HDAC) (HDAC) inhibitor is made different preparations respectively with EGF-R ELISA (EGFR) tyrosine kinase inhibitor; and the mode that adopts this area routine is with their packings or combine; the patient takes according to the chi sequence of package insert indication then, perhaps this preparation of pharmaceutical compositions is become C-MET HGFr (cMet) inhibitor; the controlled release preparation that histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor intersection discharge.
Contain C-MET HGFr (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor compositions are in preparation treatment hepatocarcinoma, pulmonary carcinoma, colon cancer, renal carcinoma, gastric cancer, cerebroma, sarcoma, cancer of pancreas, ovarian cancer, in the application in the medicine of breast carcinoma or carcinoma of prostate, C-MET HGFr in the described compositions (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor can use or simultaneously with the using in order of any priority, as can be with C-MET HGFr (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor are taken to the patient simultaneously; Also can take wherein a kind of earlier, take simultaneously again or take two kinds of medicines in addition with the order of any priority.The interval of taking for the three does not have special requirement, but the interval of preferably taking three kinds of medicines is no more than one day; Perhaps three kinds of medicines replace administration.
Among the present invention; can be with the C-MET HGFr among the present invention (cMet) inhibitor; histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor adopt the method for this area routine to be prepared into the pharmaceutical preparation that is suitable for gastrointestinal administration or parenteral administration; the present invention is preferably with C-MET HGFr (cMet) inhibitor; the pharmaceutical preparation that histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor are made gastrointestinal administration, its dosage form can be conventional tablet or capsule; or controlled release; slow releasing preparation.In the pharmaceutical preparation of C-MET HGFr of the present invention (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor compositions, according to different dosage forms and preparation specification, the content of described compositions in preparation can be counted 1-99% for quality, is preferably 10%-90%; The adjuvant that preparation uses can adopt the adjuvant of this area routine, reacts or the curative effect that do not influence medicine of the present invention is a prerequisite with the discord present composition; The preparation method of described preparation can adopt the preparation method of this area routine to be prepared.
Among the present invention; the preparation of compositions method does not have any restriction; C-MET HGFr (cMet) inhibitor, histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor three can directly mix and make preparation then; or respectively and/or corresponding auxiliary material mix and to make preparation respectively; and then be packaging together, or mix and then mix and make preparation with corresponding auxiliary material respectively according to the mode of this area routine.
The dosage of the pharmaceutical composition among the present invention can carry out suitable variation according to the dosage form difference of administration object, route of administration or medicine, but is prerequisite to guarantee that this pharmaceutical composition can reach effective blood drug level in mammalian body.
The present invention has carried out C-MET HGFr (cMet) inhibitor respectively; histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor both and three's combination arbitrarily kill Hep3B (hepatoma cell strain); A549 (lung cancer cell line); the test of HCT-116 (colon cancer cell line); results suggest; C-MET HGFr of the present invention (cMet) inhibitor; three joint groups of histon deacetylase (HDAC) (HDAC) inhibitor and EGF-R ELISA (EGFR) tyrosine kinase inhibitor close treatment hepatocarcinoma; pulmonary carcinoma and colon cancer have significant cooperative effect; the one pack system medicine or two joint groups that obviously are better than in them close; improved the curative effect of medicine greatly; reduce dosage, reduced the generation of side effect.
The specific embodiment
The invention will be further elaborated with the following Examples, but the present invention is not limited to this.
Embodiment
Reagent and method:
Cell: Hep3B (hepatoma cell strain), A549 (lung cancer cell line), HCT-116 (colon cancer cell line) are all available from American Type Culture Collection (ATCC), Rockville, MD, USA.
Medicine: institute's pharmaceutical composition is all by following method 1 or 2 described preparations of method in following examples; C-MET HGFr (cMet) inhibitor PF-02341066 is synthesized into reference to patent WO2007066187; Antibiotic FR 901228 SAHA presses document J.Med.Chem., and 1995,38,1411-1413 is synthesized into; EGF-R ELISA (EGFR) tyrosine kinase inhibitor erlotinib is synthesized into reference to patent US5747498.
Method 1: each component of accurate weighing corresponding pharmaceutical compositions, dissolve respectively with dimethyl sulfoxide, be made into the stock solution of 10mM separately, preserve down at-20 ℃, be diluted to suitable concentration with fresh culture medium during use, the solution of each component of 1 microlitre of respectively asking for then mixes standby.In all tests, the ultimate density of dimethyl sulfoxide is answered≤5g/L, so that do not influence cell activity.
With all cells in RPMI 1640 culture medium that contain 10% calf serum, 100kU/L penicillin, 100mg/L streptomycin, 37 ℃, 5%CO
2Damp condition cultivate down, in the previous day of dosing, on six orifice plates, carry out cell inoculation 2 * 10
5/ hole adds the pharmaceutical composition solution of preparation as stated above then in cell, make each component reach its working concentration, 1-18 in specifically seeing Table.
After the drug treating, measure cell death by trypan blue (Trypan Blue), cell turns into 10 minutes by carrying out pancreatin at 37 ℃ with trypsin sodium/EDTA.Because dead cell comes off from incubator enter the culture medium,, and then, mix with the trypan blue dyestuff with culture medium suspended sediment again by all cells of centrifugal collection under 1200 rev/mins.After the dyeing, count with optical microscope and hematimeter.Dyed the blue dead cell of counting by dyestuff.500 cells of picked at random are counted, and dead cell is recently expressed with the percentage that accounts for the grand total cell.
Method 2: each component of accurate weighing corresponding pharmaceutical compositions, dissolve respectively with dimethyl sulfoxide, be made into the stock solution of 10mM separately, preserve down at-20 ℃.Be diluted to suitable concentration with fresh culture medium during use, the solution for standby of each component of 1 microlitre of respectively asking for then.In all tests, the ultimate density of dimethyl sulfoxide is answered≤5g/L, so that do not influence cell activity.
With all cells in RPMI 1640 culture medium that contain 10% calf serum, 100kU/L penicillin, 100mg/L streptomycin, 37 ℃, 5%CO
2Damp condition cultivate down, in the previous day of dosing, on six orifice plates, carry out cell inoculation 2 * 10
5/ hole adds each component solution of the pharmaceutical composition of preparation as stated above with any order then in cell, make each component reach its working concentration, 19-36 in specifically seeing Table.
After the drug treating, measure cell death by trypan blue (Trypan Blue), cell turns into 10 minutes by carrying out pancreatin at 37 ℃ with trypsin sodium/EDTA.Because dead cell comes off from incubator enter the culture medium,, and then, mix with the trypan blue dyestuff with culture medium suspended sediment again by all cells of centrifugal collection under 1200 rev/mins.After the dyeing, count with optical microscope and hematimeter.Dyed the blue dead cell of counting by dyestuff.500 cells of picked at random are counted, and dead cell is recently expressed with the percentage that accounts for the grand total cell.
Tabulate down in the drug regimen shown in 1, the combination of 1-18 prepares by method 2 by the combination of method 1, the 19-36.
Table 1
PF-02341066, the SAHA of embodiment 1 different proportion and the combination Synergistic of erlotinib promote the test of Hep3B cell death, see Table 2.
Table 2
Cause in the test of hepatoma cell strain Hep 3B cell death at the investigation related compound, find
When independent use 1.0 μ MPF-02341066,2.0 μ MSAHA, 7.5 μ M erlotinibs or lower concentration, almost acellular death, even any two kinds when under low concentration, share of above-mentioned three kinds of medicines, have only 1.0 μ M PF-02341066+1.5 μ MSAHA, 1.0 μ M PF-02341066+5.0 μ M erlotinibs to share and can cause about 15% cell death, and the i.e. almost acellular death of 1.5 μ MSAHA+5.0 μ M erlotinibs of another kind of combination; But (1.0 μ M PF-02341066+1.5 μ MSAHA+5.0 μ M erlotinib) then produces the obvious synergistic effect when these three kinds of medicines share under above-mentioned low concentration, causes 43% cancer cell death; When above-mentioned three kinds of medicines make up respectively under higher concentration in twos, can cause 28% cancer cell death when also having only 1.5 μ MPF-02341066+2.0 μ MSAHA to share, all the other two kinds combinations are that 1.5 μ M PF-02341066+7.5 μ M erlotinibs and 2.0 μ MSAHA+7.5 μ M erlotinibs only cause about 15% cell death, (1.5 μ MPF-02341066+2.0 μ MSAHA+7.5 μ M erlotinib) then produces significant more synergism when the three share, and causes 93% cancer cell death.
PF-02341066, the SAHA of embodiment 2 different proportions and the combination Synergistic of erlotinib promote the test of A549 cell death, see Table 3.
Table 3
Cause in the test of lung cancer cell line A549 cell death at the investigation related compound, find when using 1.5 μ MPF-02341066,1.5 μ MSAHA, 5.0 μ M erlotinibs or lower concentration separately, almost acellular death, even any two kinds when share under low concentration of above-mentioned three kinds of medicines also only are no more than 15% cell death; But (1.0 μ M PF-02341066+1.5 μ MSAHA+5.0 μ M erlotinib) then produces the obvious synergistic effect when these three kinds of medicines share under above-mentioned low concentration, causes 43% cancer cell death; When above-mentioned three kinds of medicines make up respectively in twos, has only the cancer cell death of 15-22% under higher concentration; (1.5 μ MPF-02341066+2.0 μ MSAHA+7.5 μ M erlotinib) then produces significant more synergism when the three share, and causes 87% cancer cell death.
PF-02341066, the SAHA of embodiment 3 different proportions and the combination Synergistic of erlotinib promote the test of HCT116 cell death, see Table 4.
Table 4
Cause in the test of colon cancer cell line HCT116 cell death at the investigation related compound, find when using 1.5 μ MPF-02341066,1.5 μ MSAHA or lower concentration separately, almost acellular death, even when increasing erlotinib list concentration and being 7.5 μ M, 15% the cell death of also only having an appointment; When above-mentioned three kinds of medicines any two kinds when under low concentration, share, also only be no more than 15% cell death; But (1.0 μ MPF-02341066+1.5 μ MSAHA+5.0 μ M erlotinib) then produces the obvious synergistic effect when these three kinds of medicines share under above-mentioned low concentration, causes about 43% cancer cell death; When above-mentioned three kinds of medicines make up respectively in twos, also only be no more than 20% cancer cell death under higher concentration; (1.5 μ MPF-02341066+2.0 μ MSAHA+7.5 μ M erlotinib) then produces significant more synergism when the three share, and causes about 90% cancer cell death.
Claims (8)
1. a pharmaceutical composition is characterized in that, described compositions contains hepatocyte growth factor receptor inhibitor, Antibiotic FR 901228 and epidermal growth factor recipient tyrosine kinase inhibitor.
2. pharmaceutical composition according to claim 1; it is characterized in that the mol ratio of described hepatocyte growth factor receptor inhibitor, Antibiotic FR 901228 and epidermal growth factor recipient tyrosine kinase inhibitor is 0.3-3.0: 0.5-4.0: 1.5-15.
3. pharmaceutical composition according to claim 2; it is characterized in that the mol ratio of described hepatocyte growth factor receptor inhibitor, Antibiotic FR 901228 and epidermal growth factor recipient tyrosine kinase inhibitor is 0.75-1.5: 1.0-2.0: 3.0-7.5.
4. pharmaceutical composition according to claim 3 is characterized in that, described hepatocyte growth factor receptor inhibitor is PF-02341066, SGX523 or PHA665752; Antibiotic FR 901228 is that SAHA, MS275, LBH589, FK228, TSA, Aphacidin, depsipeptides or west reach aniline; Epidermal growth factor recipient tyrosine kinase inhibitor is gefitinib, erlotinib, Canertinib or PKI166.
5. the application of the arbitrary described pharmaceutical composition of claim 1-4 in the medicine of preparation treatment hepatocarcinoma, pulmonary carcinoma, colon cancer, renal carcinoma, gastric cancer, cerebroma, sarcoma, cancer of pancreas, ovarian cancer, breast carcinoma or carcinoma of prostate.
6. application according to claim 5; it is characterized in that; in the application in the medicine of preparation treatment hepatocarcinoma, pulmonary carcinoma, colon cancer, described hepatocyte growth factor receptor inhibitor PF-02341066, Antibiotic FR 901228 SAHA and epidermal growth factor recipient tyrosine kinase inhibitor erlotinib mol ratio are 0.75-1.5: 1.0-2.0: 3.0-7.5.
7. application according to claim 6; it is characterized in that; in the application in the medicine of preparation treatment hepatocarcinoma, pulmonary carcinoma, colon cancer, described hepatocyte growth factor receptor inhibitor PF-02341066, Antibiotic FR 901228 SAHA and epidermal growth factor recipient tyrosine kinase inhibitor erlotinib mol ratio are 1.0-1.5: 1.5-2.0: 5.0-7.5.
8. application according to claim 5; it is characterized in that the hepatocyte growth factor receptor inhibitor in the described pharmaceutical composition, Antibiotic FR 901228 and epidermal growth factor recipient tyrosine kinase inhibitor use or using in order with any priority simultaneously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910129317 CN101837129B (en) | 2009-03-19 | 2009-03-19 | Medicament composition containing cMet inhibitor, HDAC (Histone Deacetylases) inhibitor and EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910129317 CN101837129B (en) | 2009-03-19 | 2009-03-19 | Medicament composition containing cMet inhibitor, HDAC (Histone Deacetylases) inhibitor and EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101837129A true CN101837129A (en) | 2010-09-22 |
| CN101837129B CN101837129B (en) | 2012-12-12 |
Family
ID=42740961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910129317 Expired - Fee Related CN101837129B (en) | 2009-03-19 | 2009-03-19 | Medicament composition containing cMet inhibitor, HDAC (Histone Deacetylases) inhibitor and EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101837129B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103384828A (en) * | 2010-12-23 | 2013-11-06 | 雀巢产品技术援助有限公司 | Drug selection for malignant cancer therapy using antibody-based arrays |
| US10385130B2 (en) | 2016-05-11 | 2019-08-20 | Huya Bioscience International, Llc | Combination therapies of HDAC inhibitors and PD-1 inhibitors |
| US10385131B2 (en) | 2016-05-11 | 2019-08-20 | Huya Bioscience International, Llc | Combination therapies of HDAC inhibitors and PD-L1 inhibitors |
| WO2020034916A1 (en) * | 2018-08-17 | 2020-02-20 | 深圳微芯生物科技股份有限公司 | Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical use thereof |
| WO2021027912A1 (en) * | 2019-08-15 | 2021-02-18 | 深圳微芯生物科技股份有限公司 | Chidamide-containing anti-tumor pharmaceutical composition and use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050043233A1 (en) * | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
| PL1827437T3 (en) * | 2004-12-15 | 2013-06-28 | Sigma Tau Ind Farmaceuti | Combinations of therapeutic agents for treating cancer |
-
2009
- 2009-03-19 CN CN 200910129317 patent/CN101837129B/en not_active Expired - Fee Related
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103384828A (en) * | 2010-12-23 | 2013-11-06 | 雀巢产品技术援助有限公司 | Drug selection for malignant cancer therapy using antibody-based arrays |
| US10385130B2 (en) | 2016-05-11 | 2019-08-20 | Huya Bioscience International, Llc | Combination therapies of HDAC inhibitors and PD-1 inhibitors |
| US10385131B2 (en) | 2016-05-11 | 2019-08-20 | Huya Bioscience International, Llc | Combination therapies of HDAC inhibitors and PD-L1 inhibitors |
| US11535670B2 (en) | 2016-05-11 | 2022-12-27 | Huyabio International, Llc | Combination therapies of HDAC inhibitors and PD-L1 inhibitors |
| CN110833544B (en) * | 2018-08-17 | 2022-08-09 | 深圳微芯生物科技股份有限公司 | Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical application thereof |
| CN114681455A (en) * | 2018-08-17 | 2022-07-01 | 深圳微芯生物科技股份有限公司 | Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical application thereof |
| CN110833544A (en) * | 2018-08-17 | 2020-02-25 | 深圳微芯生物科技股份有限公司 | Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical application thereof |
| AU2019320922B2 (en) * | 2018-08-17 | 2022-11-17 | Shenzhen Chipscreen Biosciences, Co., Ltd. | Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical use thereof |
| WO2020034916A1 (en) * | 2018-08-17 | 2020-02-20 | 深圳微芯生物科技股份有限公司 | Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical use thereof |
| AU2019320922B9 (en) * | 2018-08-17 | 2023-03-23 | Shenzhen Chipscreen Biosciences, Co., Ltd. | Combination of histone deacetylase inhibitor and protein kinase inhibitor and pharmaceutical use thereof |
| WO2021027912A1 (en) * | 2019-08-15 | 2021-02-18 | 深圳微芯生物科技股份有限公司 | Chidamide-containing anti-tumor pharmaceutical composition and use thereof |
| CN112386593A (en) * | 2019-08-15 | 2021-02-23 | 深圳微芯生物科技股份有限公司 | Antineoplastic medicine composition containing cideramide and application thereof |
| TWI741731B (en) * | 2019-08-15 | 2021-10-01 | 大陸商深圳微芯生物科技股份有限公司 | Antitumor pharmaceutical composition comprising chidamide and use thereof |
| CN112386593B (en) * | 2019-08-15 | 2023-11-21 | 深圳微芯生物科技股份有限公司 | Anti-tumor pharmaceutical composition containing sitagliptin and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101837129B (en) | 2012-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2733929T3 (en) | A pharmaceutical combination for the treatment of melanoma | |
| CN105683197A (en) | Methods of treating various cancers using an axl/cmet inhibitor alone or in combination with other agents | |
| CN101837129B (en) | Medicament composition containing cMet inhibitor, HDAC (Histone Deacetylases) inhibitor and EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor and application thereof | |
| CN102552908B (en) | Pharmaceutical composition containing artemisinin, artemisinin derivatives and Bcl-2 inhibitor and application thereof | |
| CN101836989B (en) | Medicament composition containing tetrandrine, tetrandrine derivatives and histone deacetylase inhibitor and application thereof | |
| CN102688493B (en) | Pharmaceutical composition containing resveratrol, resveratrol derivative and Bc1-2 inhibitor, and application thereof | |
| CN101940569B (en) | Medicament composition containing sorafenib, artemisinin and artemisinin derivative and application thereof in preparing medicament for treating cancer | |
| CN102441168B (en) | Medicine composition containing apigenin, apigenin derivant and Bc1-2 inhibitor and application thereof in preparation of medicines capable of treating cancer | |
| CN102688489B (en) | Pharmaceutical composition containing triptolide, triptolide derivative and Bc1-2 inhibitor and application thereof | |
| CA3110609C (en) | 5-acetamidomethyl-oxazolidinone derivatives for use in the treatment of cancer | |
| CN101836991B (en) | Medicament composition containing sorafenib, cMet inhibitors and EGFR tyrosine kinase inhibitors and application thereof | |
| CN102441167B (en) | Pharmaceutical composition having apiolin and apiolin derivant as well as histone deaceylase inhibitors and application thereof | |
| CN101757626B (en) | Pharmaceutical composition containing insulin-like growth factor-I receptor inhibitor and histon deacetylase (HDAC) inhibitor and application thereof | |
| CN102688228B (en) | Pharmaceutical composition containing apigenin, apigenin derivative, rubescensin and rubescensin derivative, and application thereof | |
| WO2019085827A1 (en) | New uses of desmethylclozapine | |
| CN101653607B (en) | Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and mitogen extracellular kinase inhibitor and application thereof | |
| US10441564B2 (en) | Fructose analogs and their combinations as anti-cancer agents | |
| CN103127510B (en) | Medicine composition containing hepatic cell growth factor receptor inhibitor and Bcl-2 inhibitor and application thereof | |
| CN105769863B (en) | Application and anticancer medicine of the tipranavir in anticancer medicine | |
| CN101653608B (en) | Pharmaceutical composition containing hepatocyte growth factor receptor inhibitor and histone deacetylase inhibitor and application thereof | |
| CN102688490B (en) | Pharmaceutical composition containing evodiamine, evodiamine derivative and Bc1-2 inhibitor, and the application | |
| CN102440987B (en) | Drug compound of apigenin, apigenin-like derivants, artemisinin and artemisinin-like derivants and application thereof | |
| CN101653606B (en) | Pharmaceutical composition containing protein kinase B inhibitor and epidermal growth factor recipient tyrosine kinase inhibitor and application thereof | |
| CN101837128B (en) | Medicament composition containing sorafenib, MEK inhibitors and EGFR tyrosine kinase inhibitors and application thereof | |
| CN105878253A (en) | Medical application of corosolic acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121212 Termination date: 20170319 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |